| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Over the last 12 months, insiders at Zura Bio Limited have bought $0 and sold $0 worth of Zura Bio Limited stock.
On average, over the past 5 years, insiders at Zura Bio Limited have bought $4.75M and sold $13.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 80,000 shares for transaction amount of $496,000 was made by Ploos van Amstel Arnout (director) on 2024‑05‑17.
| 2024-11-25 | Sale | Thiara Parvinder | director | 1M 1.3731% | $2.73 | $2.73M | -45.75% | |
| 2024-09-11 | Sale | Thiara Parvinder | director | 3.8M 5.152% | $2.70 | $10.26M | -52.57% | |
| 2024-09-04 | Sale | Sidhu Someit | director | 51,728 0.1005% | $3.87 | $200,187 | -57.97% | |
| 2024-05-17 | Ploos van Amstel Arnout | director | 80,000 0.2491% | $6.20 | $496,000 | -46.28% | ||
| 2024-04-22 | Sidhu Someit | director | 1.19M 1.8655% | $3.13 | $3.72M | +5.44% | ||
| 2024-04-22 | Munshi Amit | director | 159,744 0.2511% | $3.13 | $499,999 | +5.44% | ||
| 2024-04-22 | Howell Michael | See Remarks | 7,987 0.0126% | $3.13 | $24,999 | +5.44% | ||
| 2024-04-22 | Nistala Kiran | Executive Vice President | 3,195 0.005% | $3.13 | $10,000 | +5.44% |
| Sidhu Someit | director | 2085418 3.2072% | $10.03M | 1 | 1 | +5.44% |
| Munshi Amit | director | 777384 1.1955% | $3.74M | 1 | 0 | +5.44% |
| Ploos van Amstel Arnout | director | 100000 0.1538% | $481,000.00 | 1 | 0 | <0.0001% |
| Howell Michael | See Remarks | 7987 0.0123% | $38,417.47 | 1 | 0 | +5.44% |
| Nistala Kiran | Executive Vice President | 3195 0.0049% | $15,367.95 | 1 | 0 | +5.44% |
| Thiara Parvinder | director | 0 0% | $0 | 0 | 2 |
$5,900,455 | 89 | -7.05% | $332.66M | |
$69,137,799 | 70 | 25.27% | $326.54M | |
$87,639,490 | 62 | 18.37% | $278.55M | |
$63,049,419 | 31 | 2.87% | $337.52M | |
$79,019,806 | 27 | 7.24% | $267.9M | |
$3,668,031 | 23 | 2.05% | $284.5M | |
$1,842,003 | 22 | -0.74% | $274.27M | |
$22,365,077 | 19 | -27.47% | $351.35M | |
$1,447,973 | 17 | 13.95% | $305.69M | |
$65,355,913 | 13 | -3.42% | $318.79M | |
$10,143,329 | 12 | 11.84% | $269.02M | |
$1,346,998 | 7 | 25.06% | $306.57M | |
$17,675,244 | 7 | 92.20% | $320.99M | |
$43,326,461 | 6 | 16.01% | $357.49M | |
$272,982 | 6 | -28.53% | $310.29M | |
Zura Bio Limited (ZURA) | $4,745,999 | 5 | -4.91% | $312.76M |
$88,549,962 | 5 | -16.91% | $352.6M | |
$2,720,023 | 3 | -11.76% | $271.85M | |
$4,888,000 | 3 | -20.50% | $352.66M |
| Increased Positions | 34 | +36.96% | 11M | +32.09% |
| Decreased Positions | 41 | -44.57% | 7M | -21.35% |
| New Positions | 19 | New | 8M | New |
| Sold Out Positions | 17 | Sold Out | 3M | Sold Out |
| Total Postitions | 85 | -7.61% | 38M | +10.73% |
| Suvretta Capital Management, Llc | $30,375.00 | 8.42% | 5.47M | +611,952 | +12.59% | 2025-09-30 |
| Vr Adviser, Llc | $25,703.00 | 7.13% | 4.63M | 0 | 0% | 2025-09-30 |
| Jpmorgan Chase & Co | $25,664.00 | 7.11% | 4.62M | -35,752 | -0.77% | 2025-09-30 |
| Great Point Partners I Lp | $21,178.00 | 5.87% | 3.82M | +645,736 | +20.37% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $16,902.00 | 4.68% | 3.05M | +3M | New | 2025-09-30 |
| Braidwell Lp | $13,724.00 | 3.8% | 2.47M | 0 | 0% | 2025-09-30 |
| Ikarian Capital, Llc | $11,834.00 | 3.28% | 2.13M | +2M | New | 2025-09-30 |
| Armistice Capital, Llc | $8,658.00 | 2.4% | 1.56M | +24,000 | +1.56% | 2025-09-30 |
| Affinity Asset Advisors, Llc | $7,073.00 | 1.96% | 1.27M | +1M | +470.6% | 2025-09-30 |
| Boothbay Fund Management, Llc | $4,574.00 | 1.27% | 824,078 | +824,078 | New | 2025-09-30 |